Sinovac vaccine for Covid offered by Chinese city for emergency use costs $60  Hindustan TimesView Full coverage on Google News
The Beijing-based Sinovac Biotech’s vaccine — called CoronaVac — is being offered in the city of Jiaxing to care givers, especially epidemic-prevention workers, public service personnel and port inspectors, and will eventually be offered to regular citizens, the state media reported on Friday, quoting officials.The Beijing-based Sinovac Biotech’s vaccine — called CoronaVac — is being offered in the city of Jiaxing to care givers, especially epidemic-prevention workers, public service personnel and port inspectors, and will eventually be offered to regular citizens, the state media reported on Friday, quoting officials.

Sinovac vaccine for Covid offered by Chinese city for emergency use costs $60 - world news - Hindustan Times

Pfizer said on Friday it may file for authorization of the COVID-19 vaccine it is developing with German partner BioNTech in late November.Pfizer said on Friday it may file for authorization of the COVID-19 vaccine it is developing with German partner BioNTech in late November.

Coronavirus vaccine: Pfizer may ask for emergency approval in late November - National | Globalnews.ca

Pfizer Inc. said it could seek emergency-use authorization for its COVID-19 vaccine in the U.S. by late November if the shot is shown to be effective in a large late-stage trial.

Pfizer confirms possible November COVID vaccine application - BNN Bloomberg

China is rapidly increasing the number of people receiving its experimental coronavirus vaccines, with a city offering one to the general public and a biotech company providing another free to students going abroad.China is rapidly increasing the number of people receiving its experimental coronavirus vaccines, with a city offering one to the general public and a biotech company providing another free to students going abroad.

China rapidly expands use of experimental COVID-19 vaccines | CTV News

An open letter from the frontrunner COVID-19 vaccine producer published Friday ends any expectations a vaccine might be available before Election Day.An open letter from the frontrunner COVID-19 vaccine producer published Friday ends any expectations a vaccine might be available before Election Day.

Pfizer CEO letter makes Thanksgiving earliest date for COVID-19 vaccine

Key workers and those at high risk from COVID-19 would be among the first to receive the jabs in the city of Jiaxing. Others include residents aged between 18 and 59 with 'urgent need for vaccination'.Key workers and those at high risk from COVID-19 would be among the first to receive the jabs in the city of Jiaxing. Others include residents aged between 18 and 59 with 'urgent need for vaccination'.

Coronavirus: Experimental £46 COVID-19 vaccine is made available to residents of Chinese city | Daily Mail Online

Treatment is safe and elicits an antibody response, preliminary results have shownTreatment is safe and elicits an antibody response, preliminary results have shown

'Enouraging' Chinese Covid vaccine shows early promise - Wales Online

403 Missing Auth Token

US pharmaceutical giant Pfizer expects to file for emergency use authorization for its Covid-19 vaccine in late November, around two weeks after the November 3 US presidential election, it said Friday. The company said it hopes to move ahead with the vaccine after safety data is available in the third week of November, immediately lifting […]

Pfizer plans to seek authorization for COVID-19 vaccine in November: company – Raw Story

Pfizer (PFE) stock is on the higher after the company announced it could submit an Emergency Use Authorization application by as soon as the end of November

Blue-Chip Drugmaker Moves Higher on Vaccine Announcement

Chinese Covid-19 vaccine candidate -- BBIBP-CorV -- that is expected to completely inactivate the SARS-CoV-2 virus, is safe and elicits an antibody response, a study published in The Lancet has found.Chinese Covid-19 vaccine candidate -- BBIBP-CorV -- that is expected to completely inactivate the SARS-CoV-2 virus, is safe and elicits an antibody response, a study published in The Lancet has found.

China's Covid-19 vax is safe, prompts antibody response: Lancet | greatandhra.com

Health authorities in Jiaxing, East China’s Zhejiang Province, announced on Thursday that the city has been administering China’s homegrown inactivated COVID-19 vaccines among high-risk groups and would gradually offer it to ordinary citizens for urgent use.

Eastern Chinese cities to offer ordinary citizens COVID-19 vaccines - Global Times

It has only been tested in 100 people, and there's no published data.It has only been tested in 100 people, and there's no published data.

Putin touts second dubious approval of an unproven COVID-19 vaccine | Ars Technica

It has only been tested in 100 people, and there's no published data.It has only been tested in 100 people, and there's no published data.

Putin touts second dubious approval of an unproven COVID-19 vaccine | Ars Technica

Trump, Biden square off in dueling town halls, U.S. Covid-19 cases reach a third peak, date set for committee vote on Barrett nomination, and other news to start your day. Trump, Biden square off in dueling town halls, U.S. Covid-19 cases reach a third peak, date set for committee vote on Barrett nomination, and other news to start your day.

Pfizer and BioNTech Vaccine Could Be Ready By the End of November. We’re All Winners. | Barron's

A $60 double-dose experimental coronavirus vaccine is being made available to some residents in an eastern Chinese city, health officials have said, the first details of a mass rollout for an as-yet unproven vaccine. Officials in Jiaxing city said Thursday residents aged between 18 and 59 with "urgent needs" can seek consultations at clinics for a Sinovac Biotech vaccine thatA $60 double-dose experimental coronavirus vaccine is being made available to some residents in an eastern Chinese city, health officials have said, the first details of a mass rollout for an as-yet

$60 experimental coronavirus vaccine rolled out in eastern Chinese city | Deccan Herald

U.S. President Donald Trump and the head of the Centers for Disease Control and Prevention (CDC) have disagreed about when a COVID-19 vaccine would become widely available. Trump has said enough vaccine would be available for every American by April, while the CDC director...U.S. President Donald Trump and the head of the Centers for Disease Control and Prevention (CDC) have disagreed about when a COVID-19 vaccine would become widely available. Trump has said enough vaccine would be available for every American by April, while the CDC director...

Explainer: When will COVID-19 vaccines be generally available in the United States? | Reuters

U.S. President Donald Trump and the head of the Centers for Disease Control and Prevention (CDC) have disagreed about when a COVID-19 vaccine would become widely available. Trump has said enough vaccine would be available for every American by April, while the CDC director said vaccines were likely to reach the general public around mid-2021, an assessment more in line with most experts.U.S. President Donald Trump and the head of the Centers for Disease Control and Prevention (CDC) have disagreed about when a COVID-19 vaccine would become widely available. Trump has said enough vaccine would be available for every American by April, while the CDC director said vaccines were likely to reach the general public around mid-2021, an assessment more in line with most experts.

Explainer: When will COVID-19 vaccines be generally available in the United States? | Article [AMP] | Reuters

COVID-19 vaccine, and China-Africa health cooperation, are their focus.

50 African diplomats visit Chinese coronavirus vaccine maker - CGTN

A Chinese drug developer is offering an experimental coronavirus vaccine to students going abroad in a strategy health experts say raises safety and ethical concerns. China National Biotech Group has two vaccine candidates out of five from Chinese developers that are in the final stages of clinicalA Chinese drug developer is offering an experimental coronavirus vaccine to students going abroad in a strategy health experts say raises safety and ethical concerns. China National Biotech Group has two vaccine candidates out of five from Chinese developers that are in the final stages of clinical

Chinese company offers coronavirus vaccine to students

The pharmaceutical giant just laid out a timetable for when it expects to be able to meet the FDA's EUA application requirements for BNT162.The pharmaceutical giant just laid out a timetable for when it expects to be able to meet the FDA's EUA application requirements for BNT162.

Pfizer Hopes to Apply for Coronavirus Vaccine Emegency Use Authorization in November | The Motley Fool

A previous clinical trial reported similar results for a different vaccine that is also based on inactivated whole SARS-CoV-2 virus, but in that study the vaccine was only tested in people aged under 60 years. The latest study, published in The Lancet Infectious Diseases journal, included participants aged between 18 and 80 years, and found that antibody responses were induced in all recipients.A previous clinical trial reported similar results for a different vaccine that is also based on inactivated whole SARS-CoV-2 virus, but in that study the vaccine was only tested in people aged under 60 years. The latest study, published in The Lancet Infectious Diseases journal, included participants aged between 18 and 80 years, and found that antibody responses were induced in all recipients.

Chinese COVID-19 vaccine candidate shows promise in human trial: Study | Health

Having struggled to contain the spread of the coronavirus, the country has put all its chips on securing access to an effective vaccine.Having struggled to contain the spread of the coronavirus, the country has put all its chips on securing access to an effective vaccine.

Indonesia Secures Access to Promising British COVID-19 Vaccine – The Diplomat

Some states, including Wisconsin, are experiencing a strain on hospitals, as Pfizer announced today that it won't likely be able to apply for emergency use for its vaccine until a few weeks after the election.Some states, including Wisconsin, are experiencing a strain on hospitals, as Pfizer announced today that it won't likely be able to apply for emergency use for its vaccine until a few weeks after the election.

US surpasses 8 million COVID-19 cases | CIDRAP

According to the recent World Bank report, an estimated 1 billion students in developing nations may be out of school. CoronavirusA World Bank report says about 1 billion students in developing countries may be out of school due to the looming second wave of COVID-19.

1 billion students in developing nations may be out of school due to second wave of COVID-19 - World Bank | Nairametrics

Vaccine developers must provide two months of safety data on half of the trial participants following the final dose of the vaccine.Vaccine developers must provide two months of safety data on half of the trial participants following the final dose of the vaccine.

A COVID-19 vaccine could arrive before the end of 2020, based on a timeline Pfizer's CEO laid out. In an open letter posted to Pfizer's website, CEO Albert Bourla wrote, "Assuming positive data, Pfizer will apply for emergency authorization use in the U. S. soon after the safety milestone is achieved in the third week of November. " COVID-19: Find the latest news on the outbreak in West Michigan by visiting the News Channel 3 coronavirus page.A COVID-19 vaccine could arrive before the end of 2020, based on a timeline Pfizer's CEO laid out. In an open letter posted to Pfizer's website, CEO Albert Bourla wrote, "Assuming positive data, Pfizer will apply for emergency authorization use in the U. S. soon after the safety milestone is achieved in the third week of November. " COVID-19: Find the latest news on the outbreak in West Michigan by visiting the News Channel 3 coronavirus page.

Pfizer could seek November vaccine authorization | WWMT

Pfizer could seek November vaccine authorization

There won’t be a coronavirus vaccine ready before Election Day, despite President Donald Trump’s repeated promises and vaccine makers’ breakneck speed.

Pfizer delivers final blow to Trump's hope for preelection vaccine - POLITICO

US pharmaceutical giant Pfizer expects to file for emergency use authorization for its Covid-19 vaccine in late November, around two weeks after the November 3 US presidential election, it said Frida…US pharmaceutical giant Pfizer expects to file for emergency use authorization for its Covid-19 vaccine in late November, around two weeks after the November 3 US presidential election, it said Frida…

Pfizer plans to seek authorization for Covid-19 vaccine next month

A Chinese COVID-19 vaccine candidate based on the inactivated whole SARS-CoV-2 virus (BBIBP-CorV) is safe and elicits an antibody response, findings from a small early-phase randomised clinical trial ...

Preliminary results find COVID-19 vaccine candidate based on inactivated SARS-CoV-2 virus is safe

The latest statistics released by the Nigeria Centre for Disease Control (NCDC) show that there are 61,194 confirmed cases of COVID-19On the 16th of October 2020, 212 new confirmed cases and 3 deaths were recorded in Nigeria

COVID-19 Update in Nigeria | Nairametrics

Dozens of companies, from biotech start-ups to Big Pharma, are racing to develop a safe and effective COVID-19 vaccine, because the world needs it and for the potential pay day.

The race for a COVID-19 vaccine heats up

Pfizer Chairman and CEO Albert Bourla said in a public statement Friday that the company won't have data showing that the vaccine is safe before the third week of November at the earliest.Pfizer Chairman and CEO Albert Bourla said in a public statement Friday that the company won't have data showing that the vaccine is safe before the third week of November at the earliest.

Pfizer COVID-19 Vaccine Delayed Until At Least Late November : Coronavirus Live Updates : NPR

The U.S. Food and Drug Administration needs at least two months of safety data before authorizing emergency use of any experimental Covid-19 vaccine. The U.S. Food and Drug Administration needs at least two months of safety data before authorizing emergency use of any experimental Covid-19 vaccine.

Pfizer Will Seek Emergency Approval For Covid-19 Vaccine In November, After Election

The companies are testing their vaccines against a placebo in healthy volunteers to see if the rate of COVID-19 infection among those who got the vaccineThe companies are testing their vaccines against a placebo in healthy volunteers to see if the rate of COVID-19 infection among those who got the vaccine

Where are we in the COVID-19 vaccine race?

Record high infection rates in the Midwest are driving the latest surge in coronavirus cases that have exceeded some daily totals reported over the summer.Record high infection rates in the Midwest are driving the latest surge in coronavirus cases that have exceeded some daily totals reported over the summer.

Outbreaks in the Midwest driving surge in COVID-19 cases

NewZimbabwe.com – The Zimbabwe News You Trust is Zimbabwe’s leading online newspaper and published by New Zimbabwe Media Ltd. The platform brings you the latest breaking News, Business, Showbiz, Sports, Diaspora and gives you everything you’ve come to expect and love.Spread This NewsMailOnLine Hopes of getting a Covid-19 vaccine were boosted again today after an experimental Chinese jab was found to be safe and produce an immune response. Every volunteer given a double-dose of state-owned firm Sinopharm’s vaccine made antibodies against SARS-CoV-2, the coronavirus that causes Covid-19. In theory, this would protect them from catching

More Covid-19 vaccine hopes as scientists say experimental Chinese jab is safe - NewZimbabwe.com

BEIJING, Oct 16 — One of China’s front-running coronavirus vaccine candidates was shown to be safe and triggered immune responses in a combined early and mid-stage test in humans, researchers said. The potential vaccine, dubbed BBIBP-CorV, is being developed by the Beijing Institute of...BEIJING, Oct 16 — One of China’s front-running coronavirus vaccine candidates was shown to be safe and triggered immune responses in a combined early and mid-stage test in humans, researchers said. The potential vaccine, dubbed BBIBP-CorV, is being developed by the Beijing Institute of...

Study: Covid-19 vaccine candidate from China’s CNBG shows promise in human test | Life | Malay Mail

Despite the fact that scientists are refusing to disclose the results of the trials, Russia claims the vaccine is safe and produced an immune response that could provide six months of protectionDespite the fact that scientists are refusing to disclose the results of the trials, Russia claims the vaccine is safe and produced an immune response that could provide six months of protection

Russia approves second Covid-19 vaccine which 'offers immunity for up to six months' - Daily Star

Pfizer said that it would likely seek emergency approval for a COVID-19 vaccine in late November, citing recent federal guidance that toughened approval…Pfizer Announcement All But Ends Worries About Pre-Election Day Vaccine Campaign Prop

Pfizer Announcement All But Ends Worries About Pre-Election Day Vaccine Campaign Prop | Talking Points Memo

NEW: Pfizer says it hopes to seek authorisation for its COVID-19 vaccine in mid-NovemberNEW: Pfizer says it hopes to seek authorisation for its COVID-19 vaccine in mid-November

Pfizer says it hopes to seek authorisation for its COVID-19 vaccine in mid-November | Euronews

NO side effects have been recorded thus far, as the development of the Covid-19 vaccine between Indonesia and China progresses.

Indonesia-China vaccine trials run smoothly | New Straits Times